Picture1 20purple 202
Xeno 20square

Xeno Biosciences

Delivering the equivalent of bypass surgery in a safe and effective pill to serve a $100B US market for obesity and related diseases

  • Stage Product In Development
  • Industry Healthcare Services
  • Location Cambridge, MA, USA
  • Currency USD
  • Founded April 2015
  • Employees 2
  • Incorporation Type C-corp
  • Website xenobiosciences.com

Company Summary

Xeno has a disruptive approach to treating obesity that mimics the highly successful treatment of gastric bypass surgery using a simple enteric-coated pill composed of components that have been shown to be safe in man. It induces the same microbiome changes caused by the surgery resulting in weight loss. Importantly, like the surgery, we anticipate that it will be effective in co-morbidities such as diabetes, CV and NASH in the obese population.